EFSA's Positive Safety Opinion on NMN Strengthens the Case for Thai FDA Registration

The European Food Safety Authority's Panel on Nutrition, Novel Foods and Food Allergens issued a positive safety opinion on beta-NMN (nicotinamide mononucleotide) on May 11, 2026, published in the EFSA Journal under DOI 10.2903/j.efsa.2026.10007. The opinion proposes 300 mg per day as a safe intake level for the general adult population. That single sentence carries real weight for Thai supplement companies working with an ingredient that has grown popular faster than the regulatory framework around it.

What EFSA Actually Concluded

The application reviewed by EFSA's panel came from EffePharm Ltd, covering NMN as a novel food ingredient for use in food supplements and general foods for adults. The panel worked through the full body of toxicological, human clinical, and metabolic evidence the applicant submitted, assessing it against the criteria set out under EU novel food regulation. Its conclusion: 300 mg per day is safe for the general adult population, with one explicit exclusion. Pregnant and lactating women were left out of the proposed safe intake level entirely, because the panel found the safety data for those groups insufficient to draw a conclusion either way.

A positive EFSA opinion is not the finish line. It moves the process to the European Commission and EU member states, who review the opinion before issuing formal novel food authorization, typically a five- to seven-month stage. Given the May 11 publication date, formal EU authorization is realistically expected before the end of B.E. 2569 (2026).

It is worth understanding why this particular ingredient drew a positive opinion when so many other longevity-marketed compounds have stalled in regulatory limbo across multiple jurisdictions. NMN's metabolic pathway, as a direct precursor to NAD+, is comparatively well characterized in the scientific literature relative to newer entrants in the same product category, and the EffePharm application appears to have benefited from a correspondingly deep body of toxicological and human clinical evidence. That combination, an established mechanism plus a well-supported dossier, is a useful pattern for any company assessing which of its own novel ingredients might be ready for a serious international regulatory submission versus which ones still need more foundational safety work before filing anywhere.

Why This Matters for a Thai FDA Dossier

NMN is already commercially active in the Thai supplement market, and its growing popularity has drawn increased scrutiny along with it. Thai FDA reviewers assessing novel ingredient registrations under Thailand's MOPH No. 376 novel food framework look to international safety assessments from recognized bodies, EFSA among them, as part of how they weigh the evidence in front of them. A formal EU novel food authorization, now a realistic near-term outcome, will be the strongest international validation NMN has received to date, and Thai FDA's review process is built to notice that kind of validation.

For a Thai supplement company, the positive opinion and its 300 mg/day proposed intake level give an ingredient safety dossier a defensible reference point it did not have before. Building that documentation into a Thai FDA submission now, ahead of formal EU authorization, positions a company to file ahead of the wave of applications that typically follows once an international novel food approval lands. The 300 mg/day figure also functions as a practical formulation benchmark: it is worth reviewing current NMN product doses against it directly, since anything formulated meaningfully above that level will need its own separate safety justification if the figure becomes a reference point Thai FDA leans on.

The population exclusion for pregnant and lactating women is not a theoretical labeling consideration either. Thai FDA labeling requirements for novel food ingredients often mirror internationally recognized restrictions of exactly this kind, and any NMN product sold in Thailand should treat this exclusion as a practical requirement to build into labeling now rather than a possibility to revisit later.

There is also a timing advantage specific to this exact moment that will not last. The gap between a positive EFSA opinion and formal EU authorization is typically the point at which an ingredient's evidence base is strongest relative to how crowded the registration queue behind it has become. Once formal EU authorization lands, expect a wave of new NMN applications across multiple jurisdictions, including Thailand, all citing the same EFSA opinion as their evidentiary anchor. Filing during the current window, while the reference is fresh and Thai FDA's own NMN queue is comparatively uncrowded, is a materially better position than filing after authorization once everyone else has caught up to the same opportunity.

What to Do With the Window That Just Opened

Pull the full opinion via DOI 10.2903/j.efsa.2026.10007 and review how EFSA structured its evidence review, since mapping that same evidence against Thai FDA dossier requirements is the fastest route to a registration-ready submission. If you already have an NMN dossier in progress, update it to cite this opinion as a primary reference; if you are starting from scratch, build around it from day one. Review your current NMN formulations against the 300 mg/day intake level directly, and check that any health claim language you are planning is supported by the same evidence base EFSA actually assessed, not language that reaches beyond what the opinion substantiates. Make sure product labeling excludes pregnant and lactating women consistent with EFSA's own restriction, and keep an eye on the European Commission's review timeline, since formal EU authorization will carry even more weight as an international reference point once it lands.

DeeMED Consulting helps supplement companies translate international safety opinions like this one into registration-ready Thai FDA novel food submissions, including novel food dossier preparation under Thailand's MOPH No. 376 framework.